It looks like nothing was found at this location. Maybe try one of the links below or a search?
Recent Posts
-
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer
Therapeutics Shareholders Vote “FOR” the Proposed Merger and Related Proposals - Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
- Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe
- Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and Founder
Most Used Categories
- Uncategorized (87)
- News (45)
Archives
Try looking in the monthly archives. 🙂